ArticleJournal of experimental & clinical cancer research : CR2026
Targeting the CAF-GDF15 axis attenuates AKT-mediated mitochondrial rewiring and chemoradiation resistance in esophageal adenocarcinoma.
Article in Journal of experimental & clinical cancer research : CR, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTherapeutic resistance in esophageal adenocarcinoma (EAC) remains poorly understood at the level of tumor-stroma interactions. We investigated whether cancer-associated fibroblast (CAF)-derived signaling contributes to chemoradiation resistance and adverse clinical outcomes in EAC, with a focus on the functional role of GDF15 within the CAF-secreted program.
methodsSerum GDF15 levels were analyzed in EAC patients before and after neoadjuvant chemoradiotherapy according to the CROSS regimen, with prognostic relevance validated in an independent cohort and public datasets. Primary EAC CAFs, EAC cell lines, and patient-derived organoids (PDOs) were used to model tumor-stroma crosstalk in 2D and 3D co-culture systems. Compartment-specific transcriptomic and proteomic profiling identified CAF-regulated pathways. Genetic depletion and antibody-mediated neutralization of GDF15 were used to assess its functional contribution, followed by evaluation of chemoradiation sensitivity, mitochondrial function, oxidative phosphorylation dependency, and AKT pathway activation.
resultsSerum GDF15 levels increased significantly following CROSS treatment, and elevated post-treatment GDF15 independently predicted poor overall survival in EAC patients. CAFs enhanced resistance to chemotherapy and radiotherapy in EAC cells and PDOs, accompanied by increased GDF15 secretion. Compartment-specific transcriptomic analysis and ELISA supported CAFs as a major source of inducible GDF15 during tumor-stroma interaction. Genetic depletion of GDF15 reduced treatment resistance, whereas recombinant GDF15 partially restored chemoresistance in GDF15-depleted models. GDF15 neutralization attenuated CAF-associated cisplatin tolerance. Mechanistically, GDF15 contributed to AKT activation and mitochondrial respiratory adaptation, including enhanced oxidative phosphorylation. Pharmacological attenuation of oxidative phosphorylation further sensitized EAC cells to cisplatin, particularly under CAF co-culture conditions.
conclusionsOur study identifies CAF-derived GDF15 as a clinically relevant and functionally targetable component of a broader CAF-secreted resistance program in EAC. GDF15 contributes to AKT-associated mitochondrial adaptation and tumor cell tolerance to chemoradiation, while elevated post-CROSS serum GDF15 serves as a prognostic biomarker. These findings support further investigation of GDF15-directed and mitochondria-targeted strategies to overcome CAF-associated treatment resistance in esophageal adenocarcinoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.